Coordination of Care: Managing Ocular Toxicity Associated with ADCs - On Demand Video - CE


Activity Description

Ocular adverse events associated with antibody-drug conjugates are common, dose-limiting, and inadequately graded by current scales. This activity reviews corneal pseudomicrocyst pathophysiology, emerging consensus grading systems, and potential preventative strategies to improve oncology-ophthalmology coordination of care.


Accreditation Statements

Sponsored by

NSUOCO



NSUOCO

Axiom Ophthalmic, LLC is a COPE-Approved Administrator.

COPELogo w AccreditationThis activity, COPE Activity Number 132954, is accredited by COPE for continuing education for optometrists. This course is approved for 0.25 hours of CE.

Course # 104546-PH
Activity #: 132954

COPE advises optometrists to contact the State or Provincial Board where they are licensed for verification of what is acceptable for license renewal.


Release Date: 05-29-2026

Expiration Date: 05-28-2027

Target Audience

This accredited educational activity is designed for optometrists.

Grant Support Statement

This activity is supported by an unrestricted educational grant from AbbVie.

 

Faculty  

Kaleb Abbott headshot

Kaleb Abbott, OD

Neel Pasricha headshot

Neel Pasricha, MD

 

Program Description

Ocular adverse events associated with antibody-drug conjugates are common, dose-limiting, and inadequately graded by current scales. This activity reviews corneal pseudomicrocyst pathophysiology, emerging consensus grading systems, and potential preventative strategies to improve oncology-ophthalmology coordination of care.



Expert Faculty


  • Kaleb Abbott, OD
  • Neel Pasricha, MD


Learning Objectives


Upon completion of this educational activity, participants should be able to:
  • Describe the standardized grading criteria for ocular side effects, differentiating between mild, moderate, and severe presentations to guide appropriate management strategies
  • Develop strategies for effective comanagement between ophthalmologists, optometrists, and oncologists, ensuring timely recognition and management of ocular toxicities that may require adjustments to cancer treatment plans

Credit Designation


This enduring educational activity is eligible for COPE-accredited continuing education credit.

Credit Hours: 0.25

Progress